![conference banner](/images/conference-banner.jpeg)
Abstract
The metabolism and elimination of drugs is mainly mediated by various cytochrome P450 (CYP) enzymes, conjugative enzymes, transporters, and efflux proteins. Members of these gene families are up-regulated at transcriptional level by drug exposure, thus leading to induction of drug metabolism and elimination. There is compelling evidence that this induction is controlled by two drug-activated nuclear receptors, constitutive androstane receptor (CAR), and pregnane X receptor (PXR). This mini-review summarizes the current knowledge of CAR and PXR, their DNA and ligand binding preferences, expression patterns and polymorphisms, mechanisms of activation, and target genes.
Keywords: nuclear receptors car, pxr, drugs elimination, cytochrome p450, efflux proteins, pregnane, target genes
Current Pharmacogenomics
Title: Nuclear Receptors CAR and PXR in Metabolism and Elimination of Drugs
Volume: 1 Issue: 2
Author(s): P. Honkakoski
Affiliation:
Keywords: nuclear receptors car, pxr, drugs elimination, cytochrome p450, efflux proteins, pregnane, target genes
Abstract: The metabolism and elimination of drugs is mainly mediated by various cytochrome P450 (CYP) enzymes, conjugative enzymes, transporters, and efflux proteins. Members of these gene families are up-regulated at transcriptional level by drug exposure, thus leading to induction of drug metabolism and elimination. There is compelling evidence that this induction is controlled by two drug-activated nuclear receptors, constitutive androstane receptor (CAR), and pregnane X receptor (PXR). This mini-review summarizes the current knowledge of CAR and PXR, their DNA and ligand binding preferences, expression patterns and polymorphisms, mechanisms of activation, and target genes.
Export Options
About this article
Cite this article as:
Honkakoski P., Nuclear Receptors CAR and PXR in Metabolism and Elimination of Drugs, Current Pharmacogenomics 2003; 1 (2) . https://dx.doi.org/10.2174/1570160033476296
DOI https://dx.doi.org/10.2174/1570160033476296 |
Print ISSN 1570-1603 |
Publisher Name Bentham Science Publisher |
Online ISSN 1570-1603 |
Related Articles
-
Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Clinical and Translational Research Challenges in Neuroendocrine Tumours
Current Medicinal Chemistry Recent Patents in Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine β-Synthase (CBS) Genes as Risk Factors for Thrombophilias
Mini-Reviews in Medicinal Chemistry Effect of Soy Isoflavone Supplementation on Endothelial Dysfunction and Oxidative Stress in Equol-Producing Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy
Current Pharmaceutical Design Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Current Progress in the Development of HIV Vaccines
Current Pharmaceutical Design Therapeutic Approaches of Leptin in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety Immune Modulation by Regulatory T Cells in Helicobacter pylori-Associated Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Potential Mechanism of Liujunzi Decoction in the Treatment of Breast Cancer based on Network Pharmacology and Molecular Docking Technology
Current Pharmaceutical Design The Use of Intravenous Aminobisphosphonates for the Treatment of Pagets Disease of Bone
Mini-Reviews in Medicinal Chemistry Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Post-Exercise Ketosis, Salivary Uric Acid and Interleukin-6 after a Simulated Wheelchair Basketball Match
Endocrine, Metabolic & Immune Disorders - Drug Targets Androgen Receptor in Human Health: A Potential Therapeutic Target
Current Drug Targets RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors
Current Cancer Drug Targets Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease
Current Pharmaceutical Design